Impaired mitochondrial metabolism is a critical cancer vulnerability for MYC inhibitors

Area of Science:

• Oncology
• Molecular Biology
• Metabolic Pathways

Background:

• MYC is a crucial oncogene driving aggressive and therapy-resistant cancers.
• Developing effective combination therapies for MYC-driven tumors remains a significant challenge.

Purpose of the Study:

• To identify novel combination strategies for MYC inhibitors.
• To investigate the mechanistic basis of synthetic lethality involving MYC inhibition.

Main Methods:

• Genome-wide CRISPR screen using the small-molecule MYC inhibitor MYCi975.
• Analysis of metabolic pathways, including oxidative phosphorylation and glycolysis.
• Assessment of tumor immune microenvironment changes and MYC dependency.

Main Results:

• MYC inhibition combined with disruption of mitochondrial complex I demonstrated synthetic lethality.
• MYC inhibition led to metabolic reprogramming, upregulating complex I.
• Targeting complex I sensitized tumors to MYCi975, increasing purine catabolism and immune cell infiltration.
• Tumor cells with lower complex I expression exhibited heightened MYC dependency.

Conclusions:

• Metabolic adaptation to MYC inhibition creates a vulnerability in mitochondrial complex I.
• Targeting complex I represents a rational and promising combination therapy strategy with MYC inhibitors.
• This approach could enhance treatment efficacy for MYC-driven cancers.